GLS.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 08:53):

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India...

Stats
Tagesvolumen	100 686
Durchschnittsvolumen	160 966
Marktkapitalisierung	100.36B
EPS	INR9.69 ( 2023-10-20 )
Last Dividend	INR21.00 ( 2023-03-24 )
Next Dividend	INR0 ( N/A )
P/E	21.34
ATR14	INR1.610 (0.20%)

Volumen Korrelation

Lang: -0.07 (neutral)

Kurz: -0.44 (neutral)

Signal:(57.261) Neutral

Glenmark Life Sciences Korrelation

10 Am meisten positiv korreliert
APCOTEXIND.NS	0.907
AMIORG.NS	0.849
RAMKY.NS	0.83
RAMRAT.NS	0.814
MAXVIL.NS	0.811
GMRINFRA.NS	0.801

10 Am meisten negativ korreliert
LTGILTBEES.NS	-0.87

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Glenmark Life Sciences Korrelation - Währung/Rohstoff

-0.16
( neutral )

-0.32
( neutral )

0.17
( neutral )

0.22
( neutral )

-0.10
( neutral )

0.36
( neutral )

Glenmark Life Sciences Finanzdaten

Annual	2023
Umsatz:	INR22.83B
Bruttogewinn:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2023
Umsatz:	INR22.83B
Bruttogewinn:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2022
Umsatz:	INR21.61B
Bruttogewinn:	INR11.47B (53.08 %)
EPS:	INR38.11

FY	2022
Umsatz:	INR21.23B
Bruttogewinn:	INR10.80B (50.88 %)
EPS:	INR35.63

Financial Reports:

No articles found.

Glenmark Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.50 (N/A)	INR0 (N/A)	INR21.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Life Sciences Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.63 - Stable (12.69%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.50	2021-11-22
Last Dividend	INR21.00	2023-03-24
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR42.00	--
Avg. Dividend % Per Year	1.99%	--
Score	4.06	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.63
Div. Directional Score	9.12	--

Next Divdend (Est)
(2024-12-18)

INR0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

4.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.50	1.40%
2022	INR10.50	1.68%
2023	INR21.00	5.03%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RAMAPHO.NS	No Dividend Player	2023-08-10	Annually	3	0.17%
KKCL.NS	Dividend Knight	2023-05-11	Semi-Annually	19	1.67%
ENIL.NS	Dividend Junior	2023-09-15	Annually	12	0.39%
ALICON.NS	Dividend Junior	2023-09-13	Annually	18	0.25%
SUTLEJTEX.NS	Dividend Junior	2023-08-18	Annually	18	1.03%
NDRAUTO.NS	Dividend Junior	2023-07-12	Annually	4	0.59%
ICICIGI.NS	Dividend Junior	2023-06-12	Annually	8	0.36%
CENTENKA.NS	Dividend Junior	2023-08-11	Annually	22	1.85%
RUBYMILLS.NS	Dividend Junior	2023-09-20	Annually	23	0.96%
LINCOLN.NS	Dividend Junior	2023-09-15	Annually	9	0.32%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.81	[0 - 0.5]
returnOnAssetsTTM	0.165	1.200	4.49	5.39	[0 - 0.3]
returnOnEquityTTM	0.204	1.500	8.85	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.37	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.64	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.687	1.500	7.29	10.00	[0.2 - 2]
debtRatioTTM	0.00602	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	408.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.61	2.00	6.69	10.00	[0 - 20]
debtEquityRatioTTM	0.00735	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.561	1.000	3.98	3.98	[0.2 - 0.8]
operatingProfitMarginTTM	0.276	1.000	6.47	6.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.72	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.801	0.800	7.99	6.39	[0.5 - 2]
Total Score				12.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.21	1.000	7.96	0	[1 - 100]
returnOnEquityTTM	0.204	2.50	9.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
dividendYielPercentageTTM	2.76	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.29	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0355	1.000	-1.613	0	[0.1 - 0.5]
Total Score				5.63

Glenmark Life Sciences

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.